

POSTER PRESENTATION

Open Access

Post-operative immune suppression is reversible with interferon gamma and independent of IL-6 pathways

ER Longbottom^{1,2*}, HDT Torrance^{1,2}, HC Owen¹, CJ Hinds^{1,2}, RM Pearse^{1,2}, MJ O'Dwyer^{1,2}

From ESICM LIVES 2015

Berlin, Germany. 3-7 October 2015

Introduction

The post-operative period is characterised by increased IL-6 production and clinical features of immune suppression. *In vitro* anti-inflammatory actions of IL-6 are mediated through suppression of interferon gamma (IFN γ) [1]. The clinical significance of IL-6 in mediating post-operative immune suppression remains unclear.

Objectives

To evaluate the role of IL-6 pathways in post-operative immune suppression and the reversibility of this phenomenon.

Methods

Patients over 45 years old undergoing elective surgery involving the gastrointestinal tract and requiring at least




Figure 1

¹Barts & the London School of Medicine, QMUL, William Harvey Research Institute, London, United Kingdom
Full list of author information is available at the end of the article

Table 1 Characteristics of patients developing infections and those remaining infection free following scheduled abdominal surgery.

	Infection N = 44 (37%)	Infection free N = 75 (63%)	P Value
Age (years)	66 (59 - 75)	64 (56 - 71)	0.19
Male sex (%)	27 (61)	47 (63)	0.89
Diabetes (%)	8 (18)	12 (16)	0.76
Current smokers (%)	10 (23)	14 (19)	0.60
Cancer diagnosis (%)	24 (55)	53 (71)	0.07
Preoperative Immunosuppression (%)	6 (14)	10 (14)	>0.99
Duration of operation (minutes)	243 (176 - 312)	195 (142 - 295)	0.06

Data are described as median with interquartile range with percentages in parenthesis

an overnight hospital stay were recruited. The primary outcome was hospital-acquired infection. IL-6 and IFN γ levels were assayed using ELISA preoperatively and at 24 and 48 hours. Pooled healthy control peripheral blood mononuclear cells (PBMCs) were cultured in perioperative serum and CD14⁺HLA-DR (mHLA-DR) geometric mean fluorescent intensity (MFI) measured in the presence and absence of interferon gamma (IFN γ) and IL-6 neutralising antibody. Data were analysed with non-parametric statistics.

Results

119 patients were recruited and 44 (37%) developed a post-operative infection a median of 9 (IQR 5-11) days postoperatively (Figure 1). IL-6 levels increased from baseline to 24 hours postoperatively ($P < 0.0001$, Figure 1A) but were then unchanged between 24 and 48 hours ($P = 0.06$, Figure 1B). Postoperative IL-6 levels correlated with the duration of the procedure ($P = 0.009$). Higher preoperative IL-6 levels were observed in patients with cancer ($P = 0.02$). IL-6 levels at 24 ($P = 0.0002$) and 48 hours ($P = 0.003$) were associated with the later occurrence of infectious complications. This pattern remained similar after adjustment for baseline characteristics. Healthy donor PBMCs incubated with postoperative serum downregulated mHLA-DR MFI when compared with serum from baseline ($n = 8$, $p = 0.008$). Culturing in the presence of IFN γ 250IU ($n = 4$) prevented this decrease whereas culturing in the presence of IL-6 neutralising antibody 15ng/ml ($n = 8$) did not.

Conclusions

IL-6 levels increase following major surgery and are associated with an increased susceptibility to post-operative infections. Serum obtained from post-operative patients induces an immunosuppressive response through an IL-6 independent pathways which is reversible with IFN γ treatment.

Grant Acknowledgment

The National Institute of Academic Anaesthesia (NIAA)

Authors' details

¹Barts & the London School of Medicine, QMUL, William Harvey Research Institute, London, United Kingdom. ²Barts Health NHS Trust, Adult Critical Care Unit, London, United Kingdom.

Published: 1 October 2015

Reference

1. Diehl S, *et al*: The two faces of IL-6 on Th1/Th2 differentiation. *Mol Immunol* 2002, **39**(9):531-6, Dec.

doi:10.1186/2197-425X-3-S1-A820

Cite this article as: Longbottom *et al*: Post-operative immune suppression is reversible with interferon gamma and independent of IL-6 pathways. *Intensive Care Medicine Experimental* 2015 **3**(Suppl 1):A820.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com